Back to search results

TXA for Long Bone Fractures in Patients on Anticoagulation

This study is looking at whether a medication called Tranexamic Acid (TXA) can help reduce blood loss during surgery for long bone fractures. TXA is already used in other orthopedic surgeries to lower bleeding and transfusion needs, and this study wants to see if it's also helpful for patients with long bone fractures who are also taking blood thinners (anticoagulation). The study will compare the estimated blood loss in patients who receive TXA to those who don't. You may be able to join if you are 18 or older and are having surgery for certain long bone fractures, such as in your thigh or shin bone. The study aims to enroll 200 participants, but its current recruitment status is unclear.

Study design
This is an interventional study planning to enroll 200 participants. It compares estimated blood loss between patients who receive Tranexamic Acid (TXA) and those who do not.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Estimated blood loss will be collected by the research team at least one month after your procedure.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07116395

Prospective Study: TXA, Anticoagulant, Orthopaedic Trauma

Not Yet Recruiting
PHASE4Ages 18+InterventionalTreatment
Arbi Nazarian, MD
~200 participants
Updated 2026-08-11 on ClinicalTrials.gov
What's tested:Tranexamic Acid (TXA)

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Estimated blood loss (EBL) comparison between those who received TXA vs no TXA
Measured over EBL note is made post-procedure by surgical team, and research team will collect data at least one month post-procedure

Conditions

Patients Undergoing Operative Fixation of Long Bone Fractures Within the Community Medical Centers System

Explore related trials

Femoral Fractures, DistalFemur FractureFracture of neck of femurIntertrochanteric fractureTibia Fracture

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Arbi Nazarian, MD · PRINCIPAL_INVESTIGATOR · University of California, San Francisco

Who to contact

Yeng Vue, MA
[email protected]
559-761-5636
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients undergoing operative fixation of long bone fractures; Included conditions include femoral neck fractures, intertrochanteric femur fractures, femoral shaft fractures, distal femur fractures, and tibial shaft fractures that undergo surgical management

What this trial measures

  • Estimated blood loss (EBL) comparison between those who received TXA vs no TXAEBL note is made post-procedure by surgical team, and research team will collect data at least one month post-procedure

    Less estimated blood loss after surgery for patients who were administered TXA